Relmada Therapeutics Statistics Share Statistics Relmada Therapeutics has 33.19M
shares outstanding. The number of shares has increased by 10%
in one year.
Shares Outstanding 33.19M Shares Change (YoY) 10% Shares Change (QoQ) 10% Owned by Institutions (%) 20.45% Shares Floating 26.73M Failed to Deliver (FTD) Shares 5,211 FTD / Avg. Volume 1.64%
Short Selling Information The latest short interest is 401.31K, so 1.21% of the outstanding
shares have been sold short.
Short Interest 401.31K Short % of Shares Out 1.21% Short % of Float 1.24% Short Ratio (days to cover) 1.73
Valuation Ratios The PE ratio is -0.2 and the forward
PE ratio is -0.62.
Relmada Therapeutics's PEG ratio is
0.01.
PE Ratio -0.2 Forward PE -0.62 PS Ratio 0 Forward PS 2.1 PB Ratio 0.44 P/FCF Ratio -0.3 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Relmada Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.45,
with a Debt / Equity ratio of 0.
Current Ratio 4.45 Quick Ratio 4.45 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-4.7M Employee Count 17 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -9.03% in the
last 52 weeks. The beta is 0.67, so Relmada Therapeutics's
price volatility has been higher than the market average.
Beta 0.67 52-Week Price Change -9.03% 50-Day Moving Average 0.63 200-Day Moving Average 0.5 Relative Strength Index (RSI) 51.7 Average Volume (20 Days) 317,251
Income Statement
Revenue n/a Gross Profit n/a Operating Income -83.89M Net Income -79.98M EBITDA -79.98M EBIT -79.98M Earnings Per Share (EPS) -2.65
Full Income Statement Balance Sheet The company has 3.86M in cash and 0 in
debt, giving a net cash position of 3.86M.
Cash & Cash Equivalents 3.86M Total Debt n/a Net Cash n/a Retained Earnings -640.88M Total Assets 21.12M Working Capital 15.96M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -51.76M
and capital expenditures 0, giving a free cash flow of -51.76M.
Operating Cash Flow -51.76M Capital Expenditures n/a Free Cash Flow -51.76M FCF Per Share -1.72
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields RLMD does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for RLMD is $1,
which is 58.7% higher than the current price. The consensus rating is "Hold".
Price Target $1 Price Target Difference 58.7% Analyst Consensus Hold Analyst Count 3
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 30, 2019. It was a
backward
split with a ratio of 1:4.
Last Split Date Sep 30, 2019 Split Type backward Split Ratio 1:4
Scores Altman Z-Score -55.46 Piotroski F-Score 1
